MedTrace Logo

Prospective Exploratory Study of a Multiomic Blood Biomarker Panel to Predict Chemotherapy-Induced Peripheral Neuropathy (CIPN)

NCT07511569 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2026-04-13

No results posted yet for this study

Summary

The goal of this prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months is to identify biomarkers to predict the overall occurrence of chronic chemotherapy-induced peripheral neuropathy (CIPN, any grade), in each of two treatment subgroups (taxanes and oxaliplatin). It involves integration of clinical data and plasma multiomic biomarkers (proteomic + metabolomic panel) analyzed via supervised machine learning to identify predictive features of CIPN.

Conditions

  • Chemotherapy Induced Neuropathic Pain
  • Neuropathy Toxic
  • Taxane-induced Peripheral Neuropathy
  • Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients

Interventions

DIAGNOSTIC_TEST

longitudinal blood sampling and standardized neurological evaluation over 6 months

Prospective, multicenter, observational cohort study with longitudinal blood sampling and standardized neurological evaluation over 6 months

Sponsors & Collaborators

  • Hopital Forcilles

    collaborator OTHER

  • AgenT

    collaborator UNKNOWN

  • Centre Hospitalier de Bligny

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2027-01-04
Primary Completion
2029-01-04
Completion
2029-06-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07511569 on ClinicalTrials.gov